Jérôme Busserolles

9PUBLICATIONS
29CO-AUTHORS
Chemical and thermal processes in energy and combustionPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 28, 2025
LPS2336, a New TREK-1 Channel Activator Identified by High Throughput Screening.

Romane Boyer, Romane Bony, Maxence Maugis

|Dec 22, 2023
Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine.

David Balayssac, Julie Durif, Céline Lambert

|Jan 11, 2022
The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.

Sylvain Lamoine, Mélissa Cumenal, David A Barriere

|Mar 27, 2021
Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity.

Vanessa Pereira, Sylvain Lamoine, Mélissa Cuménal

|Jan 06, 2021
Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.

Marie Selvy, Bruno Pereira, Nicolas Kerckhove

|Oct 26, 2020
The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and Other Drugs): review of Double-Blind, Placebo-Controlled, Randomized Clinical Trials.

Mélissa Cuménal, Marie Selvy, Nicolas Kerckhove

Pageof 2

Frequent Collaborators

4 joint publications

David Balayssac

3 joint publications

Stéphane Lolignier

3 joint publications

Marie Selvy

3 joint publications

Nicolas Kerckhove